Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Import safety summit

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Andrew von Eschenbach will moderate a discussion on the legal and regulatory safety and security requirements for the drug industry at the Import Safety Summit July 9 in Washington, the Consumer Healthcare Products Association announces. The summit, cosponsored by CHPA and other trade and advocacy groups, will include a keynote address by Health and Human Services Secretary Michael Leavitt and sessions on import safety challenges, standard-setting, auditing and certification efforts in an evolving global marketplace...

You may also be interested in...



Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”

Colfax Plans To Split To Form Separate Medtech And Fabtech Companies

The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.

What Does A Typical Refuse-To-File Letter Look Like?

Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel